{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:48:02Z","timestamp":1788220082486,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2\u201337.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg\/dL vs. 0.16 mg\/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (\u22640.1 mg\/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg\/dL) (p = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis.<\/jats:p>","DOI":"10.3390\/diagnostics12010182","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T10:57:37Z","timestamp":1642071457000},"page":"182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-8434","authenticated-orcid":false,"given":"Beatriz","family":"Frade-Sosa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Ponce","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ruiz-Esquide","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jes\u00fas","family":"Garc\u00eda-Y\u00e9benes","sequence":"additional","affiliation":[{"name":"Instituto de Salud Musculoesquel\u00e9tica, 28045 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Morl\u00e1","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Sapena","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Belen","family":"Azuaga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-7268","authenticated-orcid":false,"given":"Juan Camilo","family":"Sarmiento","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-702X","authenticated-orcid":false,"given":"Jose A.","family":"Gomez-Puerta","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimon","family":"Sanmarti","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1080\/03007995.2019.1585064","article-title":"Predicting risk for radiographic damage in rheumatoid arthritis: Comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies","volume":"35","author":"Curtis","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.60.10.924","article-title":"Predictors of radiographic joint damage in patients with early rheumatoid arthritis","volume":"60","author":"Jansen","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s10067-021-05815-3","article-title":"Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: A propensity score matching analysis","volume":"40","author":"Asai","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semarthrit.2006.04.009","article-title":"Power Doppler Ultrasound in Musculoskeletal Disease: A Systematic Review","volume":"36","author":"Joshua","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.22190","article-title":"Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug\u2013induced clinical remission: Evidence from an imaging study may explain structural progression","volume":"54","author":"Brown","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/rheumatology\/kep171","article-title":"Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: Power Doppler signal predicts short-term relapse","volume":"48","author":"Montecucco","year":"2009","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/ard.60.7.641","article-title":"Guidelines for musculoskeletal ultrasound in rheumatology","volume":"60","author":"Backhaus","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","first-page":"440","article-title":"Musculoskeletal ultrasound including definitions for ultrasonographic pathology","volume":"33","author":"Wakefield","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.10877","article-title":"Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis","volume":"48","author":"Szkudlarek","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar4431","article-title":"Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers","volume":"16","author":"Celis","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.39996","article-title":"Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria","volume":"69","author":"Smolen","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.semarthrit.2011.09.005","article-title":"Ultrasound-Defined Remission and Active Disease in Rheumatoid Arthritis: Association with Clinical and Serologic Parameters","volume":"41","author":"Dejaco","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/ard.2008.103739","article-title":"Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis","volume":"69","author":"Hammer","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e26739","DOI":"10.1097\/MD.0000000000026739","article-title":"The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine"},{"key":"ref_21","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Care Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","article-title":"Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition","volume":"19","author":"Schoels","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","article-title":"Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab","volume":"79","author":"Shafran","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","first-page":"2239","article-title":"Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants","volume":"54","author":"Ramirez","year":"2015","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/art.39164","article-title":"Brief Report: Leucine-Rich \u03b12-Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis","volume":"67","author":"Fujimoto","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1517\/17425255.2014.970165","article-title":"Pharmacogenetics of etanercept: Role of TNF-\u03b1 gene polymorphisms in improving its efficacy","volume":"10","author":"Murdaca","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.phrs.2016.06.016","article-title":"Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis","volume":"111","year":"2016","journal-title":"Pharmacol. Res."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/1\/182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:28:53Z","timestamp":1760365733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/1\/182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["diagnostics12010182"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12010182","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}